Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats Moderate. Sold as Femring, Femtrace. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Estradiol Acetate (sold as Femring, Femtrace), first approved Mar 20, 2003, with 0 new uses approved and 0 published complete response letters.
First approved: Mar 20, 2003
Applications: 2
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $7.2M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Product
Part
Spending, 2025
Change
Beneficiaries
Femring
Part D
$7.2M
+3%
2,771
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
ESTRADIOL 0.01% CREAM: $0.476 per GMGeneric · +4% in a year
ESTRADIOL 0.025 MG PATCH(1/WK): $12.33 per unitGeneric · +11% in a year
ESTRADIOL 0.025 MG PATCH(2/WK): $8.01 per unitGeneric · +27% in a year
ESTRADIOL 0.0375 MG PATCH(1/WK): $12.78 per unitGeneric · +18% in a year
ESTRADIOL 0.0375 MG PATCH(2/WK): $8.26 per unitGeneric · +18% in a year
ESTRADIOL 0.05 MG PATCH (1/WK): $12.22 per unitGeneric · +0% in a year
ESTRADIOL 0.05 MG PATCH (2/WK): $8.61 per unitGeneric · +15% in a year
ESTRADIOL 0.06 MG PATCH (1/WK): $12.27 per unitGeneric · +6% in a year
ESTRADIOL 0.06% 1.25G GEL PUMP: $3.31 per GMGeneric · -6% in a year
ESTRADIOL 0.075 MG PATCH(1/WK): $13.32 per unitGeneric · -5% in a year
ESTRADIOL 0.075 MG PATCH(2/WK): $8.23 per unitGeneric · +20% in a year
ESTRADIOL 0.1 MG PATCH (1/WK): $12.78 per unitGeneric · +6% in a year
l'estrogelA drug with a new indication and a new dosage for adjusting the start timing of controlled ovarian stimulation in assisted reproductive technology and… · Fuji Pharma Co., Ltd. · Mar 11, 2022
JulinaA drug with a new indication and a new dosage for adjusting the start timing of controlled ovarian stimulation in assisted reproductive technology and… · Bayer Yakuhin, Ltd. · Mar 11, 2022
DivigelA drug with a new indication and a new dosage for adjusting the start timing of controlled ovarian stimulation in assisted reproductive technology and… · Sun Pharma Japan Ltd. · Mar 11, 2022
Estrana(1) A drug with a new indication and a new dosage for adjusting the start timing of controlled ovarian stimulation in assisted reproductive technology and… · Hisamitsu Pharmaceutical Co., Inc. · Mar 11, 2022
EstranaA drug with a new additional indication and new dosages for the treatment of hypoestrogenism caused by hypogonadism, gonadectomy or primary ovarian… · Hisamitsu Pharmaceutical Co., Inc. · Feb 21, 2014
L'estrogelA drug with a new dosage. · Shiseido Company, Limited · Nov 25, 2011
Julina, new approvalA drug with a new route of administration indicated for the treatment of vasomotor symptoms (hot flushes and sweating) and vaginal atrophy symptoms… · Bayer Yakuhin, Ltd. · Apr 16, 2008
Clinical Trials
355 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
